<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570622</url>
  </required_header>
  <id_info>
    <org_study_id>CIRRPIO</org_study_id>
    <nct_id>NCT00570622</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis</brief_title>
  <official_title>Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the response to pioglitazone on the hepatic
      venous pressure gradient and peripheral vascular responsiveness to vasoconstrictors in
      patients with advanced (Child´s Grade B or C) cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhotic liver disease is associated with portal hypertension including elevated portal
      pressure as well as hyperdynamic circulation and low peripheral vascular resistance.
      Endothelial nitric (NO) release is impaired in liver microvasculature, upregulation of eNOS
      activity in the cirrhotic liver may constitute a new strategy to correct the increased
      hepatic vascular tone in these patients. In contrary to this impaired endothelium-dependent
      relaxation (endothelial dysfunction) and NO deficiency in the cirrhotic liver, systemic and
      splanchnic circulation of cirrhotic patients is characterized by increased vascular tone and
      hyporesponsiveness to vasoconstrictors. In addition to increasing insulin sensitivity,
      thiazolidinediones, like pioglitazone decrease oxidative stress and inflammation and improve
      endothelial function. In a randomized controlled, parallel group double-blind study 20
      Patients with advanced (Child´s Grade B or C) liver cirrhosis will receive pioglitazone or
      placebo for nine days. Portal hemodynamics and forearm blood flow response will be measured
      at baseline and after pioglitazone/placebo to investigate the effect of pioglitazone in these
      group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>portal and systemic hemodynamic parameters</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>markers of oxidative stress (malondialdehyde)</measure>
    <time_frame>9 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 60mg of pioglitazone once a day orally for 9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive Placebo orally once a day for 9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Patients receive 60mg of pioglitazone once a day orally for 9 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo once a day orally for 9 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis, grade B or C (Child-Pugh score)

        Exclusion Criteria:

          -  History of hypersensitivity to the trial drugs and contrast agent or to drugs with a
             similar chemical structure

          -  Treatment with vasoactive or non-steroidal anti-inflammatory drugs or systemic
             antibiotics one week before the study

          -  Exclusion criteria for hepatic hemodynamic investigation

          -  Cardiac, renal or respiratory failure

          -  Previous surgical or transjugular intrahepatic portosystemic shunt

          -  Insulin-dependent diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Ferlitsch A, Pleiner J, Mittermayer F, Schaller G, Homoncik M, Peck-Radosavljevic M, Wolzt M. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit Care Med. 2005 Sep;33(9):2028-33.</citation>
    <PMID>16148476</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <last_update_submitted>November 24, 2008</last_update_submitted>
  <last_update_submitted_qc>November 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Arnulf Ferlitsch, MD</name_title>
    <organization>Gastroenterology and Hepatology, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

